A federal judge overseeing hundreds of Roundup weedkiller cancer lawsuits has indicated that some claims may still proceed under alternative legal arguments, even though the Supreme Court effectively eliminated a central claim used by many plaintiffs.

In a November 14 preliminary assessment, U.S. District Judge Vince Chhabria suggested that lawsuits alleging Roundup was defectively designed might survive, depending on state law and the evidence supporting each case.

However, the judge also expressed serious doubts about whether some plaintiffs have enough evidence to prevail.

The development leaves the future of Roundup litigation uncertain as Bayer, Monsanto's parent company, seeks to resolve remaining cancer claims through a proposed multibillion-dollar settlement.

How the Supreme Court Changed Roundup Litigation

For years, people diagnosed with non-Hodgkin lymphoma after using Roundup have sued Monsanto, alleging that the company failed to adequately warn consumers about potential cancer risks associated with its glyphosate-based herbicide.

Those lawsuits have produced major jury verdicts, settlements and years of legal disputes over the safety of glyphosate.

But on June 25, 2026, the Supreme Court ruled in Monsanto v. Durnell that federal pesticide law prevents certain state-law lawsuits alleging Monsanto should have included a cancer warning on Roundup's label.

The decision centered on a conflict between federal pesticide regulations and state product liability laws.

The Environmental Protection Agency has not required a cancer warning on Roundup's label. The Supreme Court concluded that federal law generally prevents states from imposing additional or different labeling requirements through failure-to-warn lawsuits of the kind brought in Durnell.

The ruling significantly weakened one of the most common legal arguments used against Monsanto.

But it didn't necessarily eliminate every possible Roundup cancer claim.

Judge Considers Whether Defective-Design Claims Can Continue

The latest dispute focuses on an important distinction: Alleging that a company failed to warn consumers about a dangerous product isn't the same as alleging that the product itself was defectively designed.

In the first type of lawsuit, the argument is that consumers should have received stronger warnings.

In the second, plaintiffs argue that the product was unreasonably dangerous because of its design or formulation.

In his November 14 assessment, Judge Chhabria indicated that certain defective-design claims might remain legally viable despite the Supreme Court's decision.

However, whether those claims can proceed depends partly on the laws of the states where the lawsuits originated.

Some states require plaintiffs to present expert testimony supporting their defective-design allegations.

Chhabria questioned whether plaintiffs who haven't already produced such evidence should be allowed to develop it at this late stage.

He also expressed skepticism about attempts to revive lawsuits by arguing that Monsanto should have provided cancer warnings through advertising or other communications rather than product labels.

The judge's assessment was tentative. He has not issued a sweeping ruling allowing the remaining Roundup lawsuits to proceed.

Hundreds of Roundup Cases Remain Pending

The legal uncertainty affects one of the country's most prominent mass tort litigations.

According to the U.S. Judicial Panel on Multidistrict Litigation, 916 Roundup lawsuits remained pending in federal multidistrict litigation (MDL No. 2741) as of November 2, 2026.

These cases are consolidated in the Northern District of California, where Judge Chhabria has overseen coordinated pretrial proceedings for years.

The federal case count represents only part of the broader litigation. Roundup claims have also been pursued in state courts across the country.

Bayer has already spent billions resolving previous claims while continuing to defend the safety of Roundup.

The company maintains that decades of scientific research and regulatory reviews support the conclusion that glyphosate-based herbicides do not cause cancer when used as directed.

However, the International Agency for Research on Cancer classified glyphosate as probably carcinogenic to humans in 2015.

That disagreement between scientific and regulatory assessments has remained central to the controversy surrounding Roundup.

A $7.25 Billion Settlement Could Shape What Happens Next

While courts determine which legal claims remain viable, Bayer is pursuing a proposed $7.25 billion nationwide settlement intended to address current and potential future Roundup cancer lawsuits.

The proposal is separate from the Supreme Court's ruling and remains subject to court approval and other legal requirements.

Bayer executives have expressed optimism that the settlement could help bring the long-running litigation closer to resolution.

However, the agreement has not received final approval, and legal challenges could affect its implementation.

The proposed settlement also doesn't resolve the underlying scientific debate about whether glyphosate exposure causes cancer.

Instead, it represents an effort to resolve disputed legal claims and limit future litigation.

What Does This Mean for People Who Used Roundup?

The Supreme Court's ruling makes certain failure-to-warn lawsuits much harder to pursue, but it doesn't mean every Roundup cancer claim has been dismissed.

Some plaintiffs may still have claims involving defective design, negligence or other legal theories, depending on their circumstances and applicable state law.

Those claims face significant obstacles, particularly when scientific experts and evidence of alternative product designs are required.

The distinction is important for people who have followed Roundup litigation for years.

A major Supreme Court victory for Monsanto doesn't automatically resolve every pending lawsuit. Nor does a judge's willingness to consider alternative claims guarantee that those cases will succeed.

The next stage of litigation will help determine whether remaining plaintiffs can present sufficient evidence to move forward, and whether Bayer's proposed settlement ultimately brings the long-running legal battle closer to an end.